Of the 1.65 million Americans diagnosed with cancer in 2015, approximately 508,470 (31%) were classified as cancers of the genitourinary system. The most common non-skin cancer diagnosed annually in U.S. men is prostate cancer, with an incidence of 220,000, followed by cancers affecting both men and women, such as bladder cancer in 74,000 Americans and kidney cancer in 61,500 Americans. Less common cancers of the adrenal gland and male genitourinary system also comprise urologic oncology. Urologists at Weill Cornell Medicine specialize in treatment of all urologic cancers.
The Department of Urology works closely with the Sandra and Edward Meyer Cancer Center at Weill Cornell to provide our patients with a multidisciplinary access point for additional cancer treatments such as chemotherapy and radiation, as well as complementary resources such as counseling, nutritional guidance, and support groups. Our urologic oncology doctors in New York are at the forefront of their field. Many faculty members in Urology at Weill Cornell Medicine are active researchers at the Meyer Cancer Center and are working to develop new technologies & applications for urologic cancer treatment & prevention. More information on multi-disciplinary cancer care and bench-to-bedside research applications can be found on the Meyer Cancer Center website.
Recent News in Urologic Oncology:
Weill Cornell Medicine Research Highlighted by Prostate Cancer Foundation's "Top 5 Prostate Cancer Research Stories of 2017"
In this video, Dr. Douglas Scherr of discusses the clinical approach for the diagnosis and treatment of complex urologic cancers in the Department of Urology at Weill Cornell Medicine.
The Weill Cornell Urologic Oncology team in New York has extensive expertise and is internationally renowned in treating urologic cancers, using cutting-edge treatments such as robotic surgery & HIFU, as well as advanced tracking & diagnostic techniques such as MRI-Ultrasound Fusion targeted biopsies. In addition, our urologist faculty are distinguished innovators in translational research in nyc and globally, being the first to identify the Prostate Specific Membrane Antigen (PSMA) and the SPOP mutation in prostate cancer.